MyoStrain Detects and Predicts Early Cardiotoxicity from Chemotherapy

By News Release


A new study indicates that MyoStrain (fSENC) from Myocardial Solutions is an accurate and sensitive management tool that might help clinicians protect cancer patients’ heart health during chemotherapy. MyoStrain is a 10-minute, MRI-based heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction.

The article was published in Circulation: Cardiovascular Imaging.

“MyoStrain bridges a crucial gap in oncology and cardiology care. Thanks to the advances in oncology care, cancer is more treatable now than ever before. While clinical outcomes for cancer patients have improved, there is increasing concern about the potential short- and long-term side effects of these treatments, including the potentially detrimental impact they may have on the heart,” said Professor Susan Dent, MD, Medical Oncologist, Member of the Duke Cancer Institute, Co-Director of Duke Cardio-Oncology Program and study author.

“This study highlights the crucial role that MyoStrain technology may have for the early detection and prediction of cardiotoxicity during chemotherapy,” said Dr. Daniel J. Lenihan, MD, Professor of Cardiovascular Medicine, Cardio-Oncology Center Excellence Director at Washington University School of Medicine in St. Louis and study author. “We feel this could have a profound impact on patient care, focusing on optimizing heart health while also treating patients with lifesaving cancer therapy that has been shown to be cardiotoxic. With this approach, we hope to help extend patient longevity and improve quality of life.”